IBI is developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market. IBI’s lead portfolio product, IBI-10090 completed enrollment in its pivotal phase 2/3 clinical trial, in December 2012. An NDA is planned for late 2013. It was founded in 2004 and headquartered in Sunnyvale, California.